Citation Impact
Citing Papers
Dysglycemia in a community sample of people treated for schizophrenia: The Diabetes in Schizophrenia in Central-south Ontario (DiSCO) study
2007
Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)
2009
Body composition in psychotic disorders: a general population survey
2008
Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms
2009
Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study
2007
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1
2008
Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
2011
Metabolic syndrome in people with schizophrenia: a review
2009
The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology
2010
Metabolic syndrome and major depressive disorder: Co-occurrence and pathophysiologic overlap
2009
Physical illness and schizophrenia: a review of the literature
2007
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
2011
A UK Audit of Screening for the Metabolic Side Effects of Antipsychotics in Community Patients
2006
Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone
2010
Cognition and functional outcome among deaf and hearing people with schizophrenia
2007
Abnormal glucose metabolism in patients treated with antipsychotics
2007
Second-generation antipsychotics and constipation: A review of the literature
2010
The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study
2009
Severe Hyperglycemic Hyperosmolar Nonketotic Coma in a Nondiabetic Patient Receiving Aripiprazole
2008
Improved Detection of Common Variants Associated with Schizophrenia by Leveraging Pleiotropy with Cardiovascular-Disease Risk Factors
2013
Cardiovascular risk in patients with bipolar disorder
2008
Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness
2009
Quinolones in the treatment of uncomplicated urinary tract infections
1992
An atlas of genetic correlations across human diseases and traits
2015 Standout
Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: A nationwide retrospective cohort study
2010
The metabolic syndrome and schizophrenia
2008
DIAGNOSIS AND TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION
1997 Standout
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010
2013 Standout
A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study
2008
The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: A meta-analysis
2010 Standout
Fosfomycin Tromethamine
1997
Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?
2017
Cardiovascular aspects of antipsychotics
2010
Hyperactivity and Enhanced Curiosity of Mice Expressing PKB/SGK-resistant Glycogen Synthase Kinase-3 (GSK-3)
2010
Management of Schizophrenia with Obesity, Metabolic, and Endocrinological Disorders
2009
Metabolic Risk Status and Second-Generation Antipsychotic Drug Selection
2009
The role of short-chain fatty acids in microbiota–gut–brain communication
2019 Standout
Metabolic Testing Rates in 3 State Medicaid Programs After FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs
2010
How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins
2009
A systematic review and meta-analysis of exercise interventions in schizophrenia patients
2015
HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients With Schizophrenia
2009
Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders
2012
Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design
2010
Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics
2010
Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review
2009 Standout
Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: Results from the CLAMORS study
2010
Fosfomycin trometamol
1994
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia
2010
Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second‐generation antipsychotics
2008
The Effects of Undertreated Chronic Medical Illnesses in Patients With Severe Mental Disorders
2009
The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness
2009
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
2007
Physical Illness and Schizophrenia
2007
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Hyperglycemic Crises in Adult Patients With Diabetes
2009 Standout
Exercise as medicine – evidence for prescribing exercise as therapy in 26 different chronic diseases
2015 Standout
The High Prevalence of Poor Physical Health and Unhealthy Lifestyle Behaviours in Individuals with Severe Mental Illness
2011
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
2011 Standout
Diabetes and cardiovascular risk in severe mental illness: a missed opportunity and challenge for the future
2010
Obesity and Metabolic Syndrome in a Psychiatric Rehabilitation Service
2007
A review of depression and suicide risk assessment using speech analysis
2015 Standout
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins
2013
Industry sponsorship and research outcome
2017 Standout
Works of D Van Eyck being referenced
P353 - Anomalies de la tolérance au glucose chez les patients schizophrènes traités par antipsychotiques de seconde génération : étude comparative prospective de 3 mois
2007
Prevalence and incidence rates of metabolic abnormalities and diabetes in a prospective study of patients treated with second-generation antipsychotics
2007
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder
2008
Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic Medication in Patients With Schizophrenia and Schizoaffective Disorder
2008
Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study.
2006
Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review
2008
Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder
2006
Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE®
2006
Oral glucose tolerance tests in treated patients with schizophrenia.
2005
A Case Series: Evaluation of the Metabolic Safety of Aripiprazole
2006
Psychiatric Diagnosis as an Independent Risk Factor for Metabolic Disturbances
2008
Screening for Diabetes and Other Metabolic Abnormalities in Patients With Schizophrenia and Schizoaffective Disorder
2006
Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
2006
Single dose fosfomycin trometamol versus multiple dose norfloxacin over three days for uncomplicated UTI in general practice
1990
Physical health management in psychiatric settings
2010
Prevalence of the Diabetes, Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia over the Course of the Illness: a Cross-Sectional Study
2006
Prevalence of the Metabolic Syndrome in Patients with Schizophrenia Treated with Antipsychotic Medication
2006
Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia.
2007
Psychiatric diagnosis as an independent risk factor for metabolic disturbances
2008